2,3-dihydro-1-(3-mercapto-2-methyl-1-oxopropyl)-1H-indole-2-carboxylic acid | 83160-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2,3-dihydro-1-(3-mercapto-2-methyl-1-oxopropyl)-1H-indole-2-carboxylic acid
• 英文别名: 1-(3-mercapto-2S-methylpropanoyl)-indoline-2S-carboxylic acid；1-(3-Mercapto-2-methylpropanoyl)-2-indolinecarboxylic acid；1-(2-methyl-3-sulfanylpropanoyl)-2,3-dihydroindole-2-carboxylic acid
• CAS: 83160-87-6
• 化学式: C₁₃H₁₅NO₃S
• 分子量: 265.333
• InChiKey: XYVFGQVIZOKXTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,3-dihydro-1-(3-mercapto-2-methyl-1-oxopropyl)-1H-indole-2-carboxylic acid 生成 3,4,11,11a-tetrahydro-4-methyl-1H,5H-[1,4]thiazepino[4,3-a]-indole-1,5-dione
  参考文献：
  名称：

  N-(2-Substituted-1-oxoalkyl)-2,3-dihydro-1H-indole-2-carboxylic acid

  摘要：

  本文披露了在氮上用3-巯基-2-烷基-1-氧代烷基、3-磷酰基-2-烷基-1-氧代丙基或2-氨基-2-烷基-1-氧代烷基衍生物取代的2,3-二氢-1H-吲哚-2-羧酸，其作为抑制肾素转化酶和降压剂。发明的化合物（不包括披露的中间体）具有以下通用式：其中：n为1或0；R1为氢、低烷基、芳基或芳基烷基；R2为氢或低烷基；R3为氢、低烷基或芳酰基；R5为羟基、氨基或低烷氧基；X为氢、羟基、低烷基、低烷氧基或卤素；Y为氢、低烷基或芳基；R4为其中：L为O、NR7或S（其中R7为氢或低烷基）；M为R8、OR8、SR8或NR9R10（其中R8为氢、低烷基、芳基或芳基烷基；R9和R10分别为氢、低烷基或芳基）；A为O、NR13或S；R11和R12分别为氢、烷基、芳基烷基或芳基；R13为氢或低烷基；m为0、1、2或3；R20为氢或芳基；R21为羟基或低烷氧基；或其药用盐。

  公开号：

  US04350633A1
• 作为产物：
  描述：

  1-(3-Benzoylthio-2-methyl-1-oxopropyl)-2,3-dihydro-1H-indole-2-carboxylic Acid 生成 2,3-dihydro-1-(3-mercapto-2-methyl-1-oxopropyl)-1H-indole-2-carboxylic acid
  参考文献：
  名称：

  KIM, DONG, H.;MCCAULLY, R. J.

  摘要：

  DOI：

文献信息

• Angiotensin converting enzyme inhibitors: N-Substituted monocyclic and bicyclic amino acid derivatives
  作者：James L. Stanton、Norbert Gruenfeld、Joseph E. Babiarz、Michael H. Ackerman、Robert C. Friedmann、Andrew M. Yuan、William Macchia

  DOI：10.1021/jm00363a011

  日期：1983.9

  (14a-x),- N-arylalanines (15a,b),-N-cycloalkylglycines (16a-k), and -1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids (17a-d), -1,2,3,4-tetrahydroquinoline-2-carboxylic acids (18a-f), and -indoline-2-carboxylic acids (19a-k) is described. In vitro inhibition of angiotensin converting enzyme (ACE) is reported for each compound, and the structure--activity relationship for each series is discussed. The

  N-（3-巯基丙酰基）-N-芳基甘氨酸（14a-x），-N-芳基丙氨酸（15a，b），-N-环烷基甘氨酸（16a-k）和-1,2,3,4-的合成描述了四氢异喹啉-3-羧酸（17a-d），-1,2,3,4-四氢喹啉-2-羧酸（18a-f）和-二氢吲哚-2-羧酸（19a-k）。报道了每种化合物对血管紧张素转化酶（ACE）的体外抑制作用，并讨论了每个系列的结构-活性关系。讨论了ACE的体内抑制作用和各系列代表性化合物的降压作用。最有效的化合物19d的体外ACE IC50为2.6 X 10（-9）M，并且以10 mg / kg po的剂量在85 mm的自发性高血压大鼠中降低了血压。
• N-(2-Substituted-1-oxoalkyl)-2,3-dihydro-1H-indole-2-carboxylic acid
  申请人：American Home Products Corporation

  公开号：US04350633A1

  公开（公告）日：1982-09-21

  Disclosed herein are 2,3-dihydro-1H-indole-2-carboxylic acids substituted on the nitrogen with 3-mercapto-2-alkyl-1-oxoalkyl, 3-phosphoryl-2-alkyl-1-oxopropyl, or 2-amino-2-alkyl-1-oxoalkyl derivatives which act as inhibitors of angiotensin converting enzyme and as antihypertensive agents. The compounds of the invention (excluding disclosed intermediates) have the general formula: ##STR1## wherein: n is 1 or 0; R.sub.1 is hydrogen, lower alkyl, aryl or aralkyl; R.sub.2 is hydrogen or lower alkyl; R.sub.3 is hydrogen, lower alkyl or aroyl; R.sub.5 is hydroxy, amino, or lower alkoxy; X is hydrogen, hydroxy, lower alkyl, lower alkoxy, or halogen; Y is hydrogen, lower alkyl, or aryl; Y is hydrogen, lower alkyl, or aryl; R.sub.4 is ##STR2## wherein: L is O, NR.sub.7 or S (where R.sub.7 is hydrogen or lower alkyl); M is R.sub.8, OR.sub.8, SR.sub.8, or NR.sub.9 R.sub.10 (where R.sub.8 is hydrogen, lower alkyl, aryl, or aralkyl; and R.sub.9 and R.sub.10 are, independently, hydrogen, lower alkyl, or aryl); A is O, NR.sub.13 or S; R.sub.11 and R.sub.12 are, independently, hydrogen, alkyl, aralkyl or aryl; R.sub.13 is hydrogen or lower alkyl; m is 0, 1, 2, or 3; R.sub.20 is hydrogen or aryl; and R.sub.21 is hydroxy or lower alkoxy; or pharmaceutically acceptable salts thereof.

  本文披露了在氮上用3-巯基-2-烷基-1-氧代烷基、3-磷酰基-2-烷基-1-氧代丙基或2-氨基-2-烷基-1-氧代烷基衍生物取代的2,3-二氢-1H-吲哚-2-羧酸，其作为抑制肾素转化酶和降压剂。发明的化合物（不包括披露的中间体）具有以下通用式：其中：n为1或0；R1为氢、低烷基、芳基或芳基烷基；R2为氢或低烷基；R3为氢、低烷基或芳酰基；R5为羟基、氨基或低烷氧基；X为氢、羟基、低烷基、低烷氧基或卤素；Y为氢、低烷基或芳基；R4为其中：L为O、NR7或S（其中R7为氢或低烷基）；M为R8、OR8、SR8或NR9R10（其中R8为氢、低烷基、芳基或芳基烷基；R9和R10分别为氢、低烷基或芳基）；A为O、NR13或S；R11和R12分别为氢、烷基、芳基烷基或芳基；R13为氢或低烷基；m为0、1、2或3；R20为氢或芳基；R21为羟基或低烷氧基；或其药用盐。
• 1H,5H-[1,4]Thiazepino[4,3-a]indole-1,5-diones
  申请人：American Home Products Corporation

  公开号：US04303583A1

  公开（公告）日：1981-12-01

  Disclosed herein are N-(3-mercapto-2-alkyl-1-oxopropyl)-2,3-dihydro-1H-indole-2-carboxylic acids and derivatives thereof which act as inhibitors of angiotensin converting enzyme and as anti-hypertensive agents. Derivatives include those in which the 3-mercapto group is substituted with phosphate derivatives or is replaced by a variously substituted amino group. The compounds of the invention (excluding disclosed intermediates) have the general formula: ##STR1## wherein: n is 1 or 0; R.sub.1 is hydrogen, lower alkyl, aryl or aralkyl; R.sub.2 is hydrogen or lower alkyl; R.sub.3 is hydrogen, lower alkyl or aroyl; R.sub.5 is hydroxy, amino, or lower alkoxy; X is hydrogen, hydroxy, lower alkyl, lower alkoxy, or halogen; Y is hydrogen, lower alkyl, or aryl; R.sub.4 is --SH, ##STR2## wherein L is O, NR.sub.7 or S (where R.sub.7 is hydrogen or lower alkyl); M is R.sub.8, OR.sub.8, or NR.sub.9 R.sub.10 (where R.sub.8 is hydrogen, lower alkyl, aryl, or aralkyl; and R.sub.9 and R.sub.10 are, independently, hydrogen, lower alkyl, or aryl); A is O, NR.sub.13 or S; R.sub.11 and R.sub.12 are, independently, hydrogen, alkyl, aralkyl or aryl; R.sub.13 is hydrogen or lower alkyl; m is 0, 1, 2, or 3; R.sub.20 is hydrogen or aryl; and R.sub.21 is hydroxy or lower alkoxy; or pharmaceutically acceptable salts thereof.

  本文披露了N-(3-巯基-2-烷基-1-氧代丙基)-2,3-二氢-1H-吲哚-2-羧酸及其衍生物，其作为抑制肾素转化酶和降压药物。衍生物包括那些其中3-巯基基团被磷酸酯衍生物取代或被各种取代的氨基团替换的化合物。发明的化合物（不包括披露的中间体）具有以下一般式：##STR1## 其中：n为1或0；R.sub.1为氢、低烷基、芳基或芳基烷基；R.sub.2为氢或低烷基；R.sub.3为氢、低烷基或芳酰基；R.sub.5为羟基、氨基或低烷氧基；X为氢、羟基、低烷基、低烷氧基或卤素；Y为氢、低烷基或芳基；R.sub.4为--SH，##STR2## 其中L为O、NR.sub.7或S（其中R.sub.7为氢或低烷基）；M为R.sub.8、OR.sub.8或NR.sub.9 R.sub.10（其中R.sub.8为氢、低烷基、芳基或芳基烷基；R.sub.9和R.sub.10分别为氢、低烷基或芳基）；A为O、NR.sub.13或S；R.sub.11和R.sub.12分别为氢、烷基、芳基烷基或芳基；R.sub.13为氢或低烷基；m为0、1、2或3；R.sub.20为氢或芳基；R.sub.21为羟基或低烷氧基；或其药用盐。
• Renin inhibiting peptides with polar end groups
  申请人：THE UPJOHN COMPANY

  公开号：EP0329295A1

  公开（公告）日：1989-08-23

  The present invention provides novel renin-inhibiting peptides having a noncleavable transition state insert corresponding to the 10,11- position of the renin substrate (angiotensinogen) and a polyhydroxy-substituted alkyl moiety bonded directly through carbon or nitrogen to the N-terminus. Such inhibitors are useful for the diagnosis and control of renin-dependent hypertension and other related diseases.

  本发明提供了具有与肾素底物（血管紧张素原）的10,11-位置对应的不可切割过渡态插入物的新型抑制肾素的肽，以及通过碳或氮直接与N-末端结合的多羟基取代烷基基团。这些抑制剂对于诊断和控制肾素依赖性高血压和其他相关疾病非常有用。
• Renin inhibitory peptides containing suleptanic acid or derivatives thereof
  申请人：THE UPJOHN COMPANY

  公开号：EP0355065A1

  公开（公告）日：1990-02-21

  The present invention provides novel renin-inhibiting peptides having a non-cleavable transition state insert corresponding to the 10,11- position of the renin substrate (angiotensinogen) and having a suleptanic acid moiety or derivatives thereof of the formula L₁ at the N-terminus of the peptide. Such inhibitors are useful for the diagnosis and control of renin-dependent hypertension, congestive heart failure, renin dependent hyperaldosterism, other renin depen­dent cardiovascular disorders and ocular disorders. Y₁0₃S-(CH₂)n-N(R₁)--(CH₂)q--      L₁

  本发明提供了一种新型的抑制肾素的肽，其具有对应于肾素底物（血管紧张素原）的10,11位的不可切割过渡态插入物，并在肽的N-末端具有苏力帕尼酸基团或其衍生物的L₁式。这种抑制剂对于诊断和控制肾素依赖性高血压、充血性心力衰竭、肾素依赖性高醛固酮症、其他肾素依赖性心血管疾病和眼部疾病非常有用。Y₁0₃S-(CH₂)n-N(R₁)--(CH₂)q--      L₁